Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Skinvisible (SKVI) EBIT (2016 - 2025)

Skinvisible's EBIT history spans 16 years, with the latest figure at -$106057.0 for Q3 2025.

  • For Q3 2025, EBIT rose 15.13% year-over-year to -$106057.0; the TTM value through Sep 2025 reached -$580889.0, down 10.15%, while the annual FY2024 figure was -$589589.0, 20.23% down from the prior year.
  • EBIT for Q3 2025 was -$106057.0 at Skinvisible, up from -$136237.0 in the prior quarter.
  • Across five years, EBIT topped out at $159520.0 in Q2 2021 and bottomed at -$198743.0 in Q4 2024.
  • The 5-year median for EBIT is -$117716.0 (2022), against an average of -$79603.3.
  • The largest annual shift saw EBIT surged 1813.37% in 2021 before it plummeted 1519.34% in 2022.
  • A 5-year view of EBIT shows it stood at $147540.0 in 2021, then plummeted by 179.79% to -$117716.0 in 2022, then dropped by 15.99% to -$136538.0 in 2023, then plummeted by 45.56% to -$198743.0 in 2024, then skyrocketed by 46.64% to -$106057.0 in 2025.
  • Per Business Quant, the three most recent readings for SKVI's EBIT are -$106057.0 (Q3 2025), -$136237.0 (Q2 2025), and -$139852.0 (Q1 2025).